Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
DOI
 |
|
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
Peptides 125:170225 (2020)
The continued global growth in the prevalence of obesity coupled with the limited number of efficacious and safe treatment options elevates the importance of innovative pharmaceutical approaches. Combinatorial strategies that harness the metabolic benefits of multiple hormonal mechanisms have emerged at the preclinical and more recently clinical stages of drug development. A priority has been anti-obesity unimolecular peptides that function as balanced, high potency poly-agonists at two or all the cellular receptors for the endocrine hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This report reviews recent progress in this area, with emphasis on what the initial clinical results demonstrate and what remains to be addressed.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Obesity ; Type 2 Diabetes ; Poly-agonism ; Gip ; Glp-1 ; Glucagon; Dependent Insulinotropic Polypeptide; High-fat Diet; Peptide-1 Receptor; Body-weight; Bariatric Surgery; Corrects Obesity; Glycemic Control; Clinical-trials; Hybrid Peptide; Co-agonism
ISSN (print) / ISBN
0196-9781
e-ISSN
1873-5169
Zeitschrift
Peptides
Quellenangaben
Band: 125,
Artikelnummer: 170225
Verlag
Elsevier
Verlagsort
New York, NY
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Diabetes and Obesity (IDO)